GW&K Investment Management LLC Sells 16,620 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

GW&K Investment Management LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,745,641 shares of the biopharmaceutical company’s stock after selling 16,620 shares during the period. Halozyme Therapeutics accounts for 0.7% of GW&K Investment Management LLC’s portfolio, making the stock its 27th biggest position. GW&K Investment Management LLC’s holdings in Halozyme Therapeutics were worth $83,459,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in HALO. Private Advisor Group LLC boosted its stake in shares of Halozyme Therapeutics by 6.2% during the 3rd quarter. Private Advisor Group LLC now owns 24,163 shares of the biopharmaceutical company’s stock worth $1,383,000 after buying an additional 1,410 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Halozyme Therapeutics by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,582 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 782 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in Halozyme Therapeutics by 7.2% during the third quarter. State of Alaska Department of Revenue now owns 14,838 shares of the biopharmaceutical company’s stock worth $849,000 after acquiring an additional 995 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Halozyme Therapeutics by 32.8% during the third quarter. Nisa Investment Advisors LLC now owns 5,495 shares of the biopharmaceutical company’s stock valued at $315,000 after purchasing an additional 1,358 shares during the last quarter. Finally, Diversify Advisory Services LLC grew its stake in Halozyme Therapeutics by 8.5% in the third quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 418 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. HC Wainwright upped their price objective on Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Wells Fargo & Company dropped their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Benchmark restated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, JMP Securities raised their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $57.70 on Friday. The firm’s fifty day moving average price is $54.08 and its two-hundred day moving average price is $54.71. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The company has a market cap of $7.11 billion, a P/E ratio of 16.82, a P/E/G ratio of 0.42 and a beta of 1.25. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the sale, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. This represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,697 shares of company stock valued at $1,461,001. Insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.